The report will contain:

• Market data on therapy area – facts and figures
• An analysis of deal making and trends to provide pointers to what is likely to happen in the therapy area.
• Who are the top players?
• What impact has the credit crunch and emerging markets in deal making in this therapy area?
• Broad predictions of direction of the market with quotes from leading industry people.
• Which technologies are driving the deals and why are they attractive
• A reference section with case studies of handpicked deals with SEC analysis where available

View the Table of Contents

The Definitive Industry Reference, this report is a “must read” for anyone involved in deal making who wants to get the maximum value from their next deal.

"The report sets out to give the reader a full insight into determining valuation and royalties and the huge impact that these terms can have on deals and their ultimate survival."

Dr Fintan Walton,
CEO of PharmaVentures

The content has been formulated by leveraging over 15 years of experience in assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making, and in response to valued feedback from our extensive market research. This report follows on from the publication of previous top selling reports on the topic of royalty rates.

• Clear guidance on the best methodologies to use when calculating Royalty Rates to assist with vital decision making 
• Opinions and advice from leading industry deal makers on how to calculate Royalty Rates 
• Contextual information – The report reviews the appropriate methodologies to use as part of the process to calculate Royalty Rates in-depth. It explores questions such as: “What do royalties mean in terms of value?” and “Where do royalties fit within the deal?” 
• More case studies – PharmaVentures highlights the issues and pitfalls so that you can avoid them

Click here to view the full table of contents

Drugs with annual sales totaling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commercial viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new PharmaDeals® Report, covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

Click here to view the full table of contents

This report is a must-have report for all involved in business development, marketing or competitive intelligence in understanding what lies behind such deals and how they come about.

In deal making, it can be hard to pick the optimum deal type for your situation. Even the most accomplished deal maker is unlikely to have been involved in each and every type of deal.

This indispensable report answers numerous key questions including:

• What is the rationale for different deal structures?
• What is the most relevant deal type to use in a particular situation?
• What are the key issues that must be considered for each deal type?
• How do I value these deals?
• What do these deals look like in real life?
• What is the impact of the economic downturn on deals?

The report analyses each type of deal in detail and, in addition, is supported by extensive analysis and case studies of real life examples from PharmaDeals® v2 Agreements and PharmaDeals Review.

Click here to view the full table of contents

Building on an established reputation in the area of deal negotiation and valuation, PharmaVentures is pleased to announce the release of their revised, best-selling Industry Standard Report.

This important Report takes into account all recent developments and focuses on the issues of most concern to business development and licensing professionals within the large pharmaceutical, biotechnology and academic network. It fully addresses financial modeling and provides detailed valuation examples. Its content has been formulated and thoroughly tested. The Report will:

• Provide a thorough understanding of robust valuation methodologies
• Enable more rigorous economic portfolio analysis
• Offer greater transparency in portfolio analysis
• Assist the formulation of attractive deal structures
• Permit accurate comparison of alternative deals
• Highlight the value creation process
• Minimise risk in future deals

It is an essential reference source for all those aiming to maximise deal values and minimise risk.

Click here to view the full table of contents

The report, written by Bird & Bird's leading lawyers, sets out the essential issues concerning the intellectual property regime and the application of competition law in the pharmaceuticals sector, and the sector-specific regulatory provisions affecting competition.

The resulting case law both at EU level and at national level implementing the EU rules on competition and the related regulatory developments are central to the strategic decisions of pharmaceuticals suppliers.

Looking at leading cases within the pharmaceuticals sector, involving companies such as GlaxoSmithKline, Boehringer Ingelheim, Bayer, Organon, Johnson & Johnson, AstraZeneca, Napp Pharmaceuticals and Genzyme to illustrate the key points, the report examines essential issues, including the following:

• How legislation and case law has set out limits in various areas on the extents to which intellectual property owners can enforce their patents
• Parallel importation under the EC rules on free circulation of goods and the EC competition rules, agreements and conduct restricting parallel imports and exports
• Meaning of an agreement under the EC competition rules
• Conduct of dominant suppliers with regard to pricing issues
• Commission guidelines on the application of competition rules to R&D collaboration agreements
• Effect of regulation on technology licensing, marketing and distribution agreements

UK and EC competition authorities' commitment to private enforcement of the competition rules to combat cartels

Click here to view the full table of contents

The report covers those essential market changing initiatives which make tomorrow’s drug market different from today’s. Successful deal making has accurate valuation at its heart. Anything that impacts a drugs ability to achieve in the future a fair and profitable market price impacts its value today. The current market is more challenging than ever before. Payer-driven price negotiation for reimbursement, and cost-containment programmes to control prescribing both challenge the traditional pricing model the industry has used to generate valuable R&D resource to further the search for innovation and better disease control.

Click here to view the executive summary

Published reports include:
PharmaDeals® Deal Making Spotlight Reports
Deal Making Spotlight on Pfizer
Deal Making Spotlight on sanofi-aventis
Deal Making Spotlight on GlaxoSmithKline
Deal Making Spotlight on Johnson & Johnson
Deal Making Spotlight on Novartis

Detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.

Click here to view the table of contents

• The virus and its history
• Key industry insight
• An analysis of the market
• Summary of influenza-related deals 

View the table of contents

This report provides in-depth information and practical advice relating to the partnering process. Based on PharmaVentures' experiences of working with pharmaceutical and biotechnology companies worldwide, this comprehensive report provides an insight into the challenges and rewards of the partnering process. The report includes quotations documenting industry-partnering experiences, and is a must read for anyone needing to complete & manage deals.

Click here to view the executive summary